To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomised Phase II study of panitumumab monotherapy and panitumumab plus 5‑fluorouracil as first‑line therapy for RAS and BRAF wild‑type metastatic CRC (AGITG and CTC study).
See ANZCTR for full trial details >
|
Trial Summary: |
The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer. |
|
Supported By: |
AGITG |
|
Eligibility: |
Elderly patients, >70 years, with histologically confirmed RAS and BRAF wild‑type metastatic CRC who have not have previously received hemotherapy and/or targeted therapy for their metastatic disease who are suitable for panitumumab alone or panitumumab plus 5‑FU |
|
Registration ID: |
ACTRN12618000233224 |
|
Participation: |
Australia |
|
Australian Lead Group: |
AGITG |
|
Status: |
Closed |
|
Activation Date: |
20.06.2018 |
|
Chairs: |
Matthew Burge |
|
Contact: |